Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Malignant Lymphoma

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 89 articles: HTML format

Single Articles

July 2026
1. EYRE TA, Song Y, Hermine O, Shuang Y, et al
   Erratum: Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.
   J Clin Oncol. 2026 Jul 14:JCO2601699. doi: 10.1200/JCO-26-01699.
   PubMed    
   
   
   
2. LADETTO M, Gutmair K, Tavarozzi R, Pawlikowski A, et al
   Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.
   J Clin Oncol. 2026 Jul 14:JCO2600705. doi: 10.1200/JCO-26-00705.
   PubMed     Abstract available
   
   
   
3. MATASAR M, Li Z, Vassilakopoulos TP, Sancho JM, et al
   Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.
   J Clin Oncol. 2026 Jul 6:JCO2502849. doi: 10.1200/JCO-25-02849.
   PubMed     Abstract available
   
   
   
4. EYRE TA, Song Y, Hermine O, Shuang Y, et al
   Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.
   J Clin Oncol. 2026 Jul 1:JCO2600550. doi: 10.1200/JCO-26-00550.
   PubMed     Abstract available
   
   
   June 2026
5. WILSON MR, Lewis KL, Kirkwood AA, Cwynarski K, et al
   High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.
   J Clin Oncol. 2026 Jun 11:JCO2600947. doi: 10.1200/JCO-26-00947.
   PubMed     Abstract available
   
   
   
6. FRIEDBERG JW
   End of Methotrexate for CNS Prophylaxis in Diffuse Large B-Cell Lymphoma.
   J Clin Oncol. 2026 Jun 11:JCO2601188. doi: 10.1200/JCO-26-01188.
   PubMed    
   
   
   May 2026
7. LEONARD JP, Trneny M, Zhang H, Nowakowski GS, et al
   Erratum: Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.
   J Clin Oncol. 2026 May 13:JCO2601085. doi: 10.1200/JCO-26-01085.
   PubMed    
   
   
   April 2026
8. UPPAL M, Bhinder B, Marderstein AR, Lee Batlevi C, et al
   Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.
   J Clin Oncol. 2026 Apr 29:JCO2501928. doi: 10.1200/JCO-25-01928.
   PubMed     Abstract available
   
   
   
9. STEPAN L, Ansari S, Abramson JS, Okal A, et al
   Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.
   J Clin Oncol. 2026 Apr 27:JCO2503051. doi: 10.1200/JCO-25-03051.
   PubMed     Abstract available
   
   
   
10. MEHTA-SHAH N, Zinzani PL, Jacobsen ED, Zain J, et al
    Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma.
    J Clin Oncol. 2026 Apr 22:101200JCO2503120. doi: 10.1200/JCO-25-03120.
    PubMed     Abstract available
    
    
    
11. LEONARD JP, Trneny M, Zhang H, Nowakowski GS, et al
    Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.
    J Clin Oncol. 2026 Apr 16:JCO2501770. doi: 10.1200/JCO-25-01770.
    PubMed     Abstract available
    
    
    
12. PEMMARAJU N, Marconi G, Montesinos P, Lane AA, et al
    Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.
    J Clin Oncol. 2026;44:861-873.
    PubMed     Abstract available
    
    
    January 2026
13. CUSICK A
    Smell.
    J Clin Oncol. 2026;44:252-253.
    PubMed     Abstract available
    
    
    
14. CASTELLINO SM, Li H, Herrera AF, LeBlanc M, et al
    Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.
    J Clin Oncol. 2026 Jan 9:JCO2500203. doi: 10.1200/JCO-25-00203.
    PubMed     Abstract available
    
    
    
15. HAYASHI RJ, Winter SS, Dunsmore KP, Devidas M, et al
    Erratum: Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434.
    J Clin Oncol. 2026 Jan 5:JCO2502779. doi: 10.1200/JCO-25-02779.
    PubMed    
    
    
    December 2025
16. KRUPKA JA, Moutsopoulos I, Cutmore NH, Trethewey CS, et al
    Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.
    J Clin Oncol. 2025 Dec 22:JCO2501587. doi: 10.1200/JCO-25-01587.
    PubMed     Abstract available
    
    
    
17. WANG S, Nijland M, Strobbe L, Oosterveld M, et al
    Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.
    J Clin Oncol. 2025 Dec 12:JCO2501712. doi: 10.1200/JCO-25-01712.
    PubMed     Abstract available
    
    
    
18. POPHALI PA, Kenkre VP, Hayes CA
    Bridging the Gap: Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: Long-Term Benefit, Yet Real-World Complexity.
    J Clin Oncol. 2025 Dec 10:JCO2502323. doi: 10.1200/JCO-25-02323.
    PubMed    
    
    
    
19. JURCZAK W, Kwiatek M, Czyz J, Roberto de Mattos E, et al
    BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    J Clin Oncol. 2025 Dec 9:JCO2502380. doi: 10.1200/JCO-25-02380.
    PubMed     Abstract available
    
    
    
20. WOYACH JA, Qiu L, Grosicki S, Wrobel T, et al
    Pirtobrutinib Versus Ibrutinib in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    J Clin Oncol. 2025 Dec 7:JCO2502477. doi: 10.1200/JCO-25-02477.
    PubMed     Abstract available
    
    
    
21. MAURER MJ, Prochazka VK, El-Galaly TC, Flowers CR, et al
    FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma.
    J Clin Oncol. 2025 Dec 2:JCO2500892. doi: 10.1200/JCO-25-00892.
    PubMed     Abstract available
    
    
    November 2025
22. MORSCHHAUSER F, Salles G, Sehn LH, Herrera AF, et al
    Erratum: Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2025 Nov 20:JCO2502667. doi: 10.1200/JCO-25-02667.
    PubMed    
    
    
    
23. MAZIARZ RT, Bishop MR, Tam CS, Borchmann P, et al
    Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.
    J Clin Oncol. 2025 Nov 18:JCO2500507. doi: 10.1200/JCO-25-00507.
    PubMed     Abstract available
    
    
    
24. DICKINSON MJ
    Antibody-Drug Conjugates and Bispecific Antibodies for Lymphoma: Partners of Convenience or a Perfect Match.
    J Clin Oncol. 2025 Nov 7:JCO2502200. doi: 10.1200/JCO-25-02200.
    PubMed    
    
    
    October 2025
25. HUTCHINGS M, Sureda A, Bosch F, Larsen TS, et al
    Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial.
    J Clin Oncol. 2025 Oct 20:JCO2500992. doi: 10.1200/JCO-25-00992.
    PubMed     Abstract available
    
    
    
26. NEELAPU SS, Chavez JC, Sehgal AR, Epperla N, et al
    Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.
    J Clin Oncol. 2025 Oct 16:JCO2500668. doi: 10.1200/JCO-25-00668.
    PubMed     Abstract available
    
    
    
27. ROSSI D
    Assessing Remission in Diffuse Large B-Cell Lymphoma: Will Minimal Residual Disease Add Value to Positron Emission Tomography?
    J Clin Oncol. 2025 Oct 7:JCO2501932. doi: 10.1200/JCO-25-01932.
    PubMed    
    
    
    
28. BUDDE LE, Zhang H, Kim WS, Maruyama D, et al
    Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial.
    J Clin Oncol. 2025 Oct 2:101200JCO2501957. doi: 10.1200/JCO-25-01957.
    PubMed     Abstract available
    
    
    September 2025
29. GALLAMINI A, Tarella C, Viviani S, Rossi A, et al
    Erratum: Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL
    J Clin Oncol. 2025 Sep 26:JCO2502137. doi: 10.1200/JCO-25-02137.
    PubMed    
    
    
    
30. MORSCHHAUSER F, Salles G, Sehn LH, Herrera AF, et al
    Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2025 Sep 24:JCO2500925. doi: 10.1200/JCO-25-00925.
    PubMed     Abstract available
    
    
    August 2025
31. ROSCHEWSKI M, Kurtz DM, Westin JR, Lynch RC, et al
    Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma.
    J Clin Oncol. 2025 Aug 13:101200JCO2501534. doi: 10.1200/JCO-25-01534.
    PubMed     Abstract available
    
    
    
32. DE MASSON A, Beylot-Barry M, Ram-Wolff C, Mear JB, et al
    Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score-Matched Controlled Prospective Study.
    J Clin Oncol. 2025;43:2461-2466.
    PubMed     Abstract available
    
    
    July 2025
33. SHARMAN JP, Munir T, Grosicki S, Roeker LE, et al
    Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
    J Clin Oncol. 2025 Jul 29:JCO2501700. doi: 10.1200/JCO-25-01700.
    PubMed    
    
    
    
34. RADHAKRISHNAN VS, Johnson PWM
    Antibody-Based Therapies for the Treatment of Hodgkin Lymphoma in Older Patients.
    J Clin Oncol. 2025 Jul 17:JCO2501022. doi: 10.1200/JCO-25-01022.
    PubMed    
    
    
    
35. FERDINANDUS J, Kaul H, Fossa A, Huttmann A, et al
    Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort o
    J Clin Oncol. 2025 Jul 17:JCO2500439. doi: 10.1200/JCO-25-00439.
    PubMed     Abstract available
    
    
    
36. KAMDAR M, Solomon SR, Arnason J, Johnston PB, et al
    Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study.
    J Clin Oncol. 2025 Jul 7:JCO2500399. doi: 10.1200/JCO-25-00399.
    PubMed     Abstract available
    
    
    June 2025
37. SHARMAN JP, Munir T, Grosicki S, Roeker LE, et al
    Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
    J Clin Oncol. 2025 Jun 27:JCO2501356. doi: 10.1200/JCO-25-01356.
    PubMed    
    
    
    
38. LOCKE FL, Le Gall JB, Fisher PW, Neelapu SS, et al
    Reply to: Optimizing Allogeneic Chimeric Antigen Receptor T-Cell Persistence in Relapsed/Refractory Large B-Cell Lymphoma: The Role of KIR Matching.
    J Clin Oncol. 2025 Jun 23:JCO2500955. doi: 10.1200/JCO-25-00955.
    PubMed    
    
    
    
39. SHIMAZU Y
    Optimizing Allogeneic Chimeric Antigen Receptor T-Cell Persistence in Relapsed/Refractory Large B-Cell Lymphoma: The Role of KIR Matching.
    J Clin Oncol. 2025 Jun 23:JCO2500394. doi: 10.1200/JCO-25-00394.
    PubMed    
    
    
    
40. MINSON A, Verner E, Giri P, Butler J, et al
    Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study.
    J Clin Oncol. 2025 Jun 18:JCO2500481. doi: 10.1200/JCO-25-00481.
    PubMed     Abstract available
    
    
    
41. RUTHERFORD SC, Li H, Herrera AF, LeBlanc M, et al
    Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826.
    J Clin Oncol. 2025 Jun 16:JCO2500204. doi: 10.1200/JCO-25-00204.
    PubMed     Abstract available
    
    
    
42. SHARMAN JP, Munir T, Grosicki S, Roeker LE, et al
    Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
    J Clin Oncol. 2025 Jun 6:JCO2500166. doi: 10.1200/JCO-25-00166.
    PubMed     Abstract available
    
    
    May 2025
43. SHADMAN M, Munir T, Ma S, Lasica M, et al
    Zanubrutinib and Venetoclax for Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results.
    J Clin Oncol. 2025 May 31:JCO2500758. doi: 10.1200/JCO-25-00758.
    PubMed     Abstract available
    
    
    
44. EYRE TA, Cheah CY, Sarkozy C, Kumar A, et al
    Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase-Targeted Approaches.
    J Clin Oncol. 2025 May 29:JCO2500146. doi: 10.1200/JCO-25-00146.
    PubMed     Abstract available
    
    
    
45. ARUNACHALAM AK, Gilmour CK, Melenhorst JJ
    Optimizing Chimeric Antigen Receptor T-Cell Therapy for Mantle Cell Lymphoma.
    J Clin Oncol. 2025 May 19:JCO2500568. doi: 10.1200/JCO-25-00568.
    PubMed    
    
    
    
46. WANG M, Salek D, Belada D, Song Y, et al
    Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.
    J Clin Oncol. 2025 May 1:101200JCO2500690. doi: 10.1200/JCO-25-00690.
    PubMed     Abstract available
    
    
    April 2025
47. KIRKWOOD AA, Goulden N, Moppett J, Samarasinghe S, et al
    High-Dose Methotrexate in Children and Young Adults With ALL and Lymphoblastic Lymphoma: Results of the Randomized Phase III Study UKALL 2011.
    J Clin Oncol. 2025 Apr 7:JCO2401851. doi: 10.1200/JCO-24-01851.
    PubMed     Abstract available
    
    
    March 2025
48. SHAH NN, Colina AS, Johnson BD, Szabo A, et al
    Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma.
    J Clin Oncol. 2025 Mar 31:JCO2402158. doi: 10.1200/JCO-24-02158.
    PubMed     Abstract available
    
    
    February 2025
49. PHILLIPS TJ
    Reply to: Glofitamab for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.
    J Clin Oncol. 2025 Feb 14:JCO2500088. doi: 10.1200/JCO-25-00088.
    PubMed    
    
    
    
50. SHIMAZU Y, Shimazu Y
    Glofitamab for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.
    J Clin Oncol. 2025 Feb 14:JCO2402259. doi: 10.1200/JCO-24-02259.
    PubMed    
    
    
    
51. LOCKE FL, Munoz JL, Tees MT, Lekakis LJ, et al
    Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies.
    J Clin Oncol. 2025 Feb 13:101200JCO2401933. doi: 10.1200/JCO-24-01933.
    PubMed     Abstract available
    
    
    January 2025
52. PARK JH, Palomba ML, Perica K, Devlin SM, et al
    Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma.
    J Clin Oncol. 2025 Jan 30:JCO2402424. doi: 10.1200/JCO-24-02424.
    PubMed     Abstract available
    
    
    
53. CROMBIE JL, LaCasce AS
    Targeting CD30 in Diffuse Large B-Cell Lymphoma: Where Does It Fit in?
    J Clin Oncol. 2025 Jan 7:JCO2402483. doi: 10.1200/JCO-24-02483.
    PubMed    
    
    
    
54. BARTLETT NL, Hahn U, Kim WS, Fleury I, et al
    Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2025 Jan 7:JCO2402242. doi: 10.1200/JCO-24-02242.
    PubMed     Abstract available
    
    
    December 2024
55. FOSS FM, Kim YH, Prince HM, Akilov OE, et al
    Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.
    J Clin Oncol. 2024 Dec 19:JCO2401549. doi: 10.1200/JCO-24-01549.
    PubMed     Abstract available
    
    
    
56. TORKA P, Feldman T, Savage KJ, Ganesan N, et al
    Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.
    J Clin Oncol. 2024 Dec 11:JCO2401278. doi: 10.1200/JCO-24-01278.
    PubMed     Abstract available
    
    
    
57. SHADMAN M, Munir T, Robak T, Brown JR, et al
    Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.
    J Clin Oncol. 2024 Dec 8:JCO2402265. doi: 10.1200/JCO-24-02265.
    PubMed     Abstract available
    
    
    November 2024
58. 
    Erratum: Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma.
    J Clin Oncol. 2024 Nov 7:JCO2402371. doi: 10.1200/JCO-24-02371.
    PubMed    
    
    
    
59. RICHARD MA, Yan C, Chen Y, Gibson CJ, et al
    Sex-Based Differences in Risk of Therapy-Related Myeloid Neoplasms.
    J Clin Oncol. 2024;42:3739-3750.
    PubMed     Abstract available
    
    
    October 2024
60. PHILLIPS TJ, Carlo-Stella C, Morschhauser F, Bachy E, et al
    Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study.
    J Clin Oncol. 2024 Oct 4:JCO2302470. doi: 10.1200/JCO.23.02470.
    PubMed     Abstract available
    
    
    September 2024
61. HEGER JM, Mammadova L, Mattlener J, Sobesky S, et al
    Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma.
    J Clin Oncol. 2024 Sep 30:JCO2301867. doi: 10.1200/JCO.23.01867.
    PubMed     Abstract available
    
    
    
62. TOURNILHAC O, Altmann B, Friedrichs B, Bouabdallah K, et al
    Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma).
    J Clin Oncol. 2024 Sep 13:JCO2400554. doi: 10.1200/JCO.24.00554.
    PubMed     Abstract available
    
    
    August 2024
63. MARTELLI M, Ceriani L, Ciccone G, Ricardi U, et al
    Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results.
    J Clin Oncol. 2024 Aug 19:JCO2401373. doi: 10.1200/JCO-24-01373.
    PubMed     Abstract available
    
    
    
64. JAIN MD, Spiegel JY, Nastoupil LJ, Tamaresis J, et al
    Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
    J Clin Oncol. 2024 Aug 2:JCO2302786. doi: 10.1200/JCO.23.02786.
    PubMed     Abstract available
    
    
    July 2024
65. WILLIAMS AM, Rodday AM, Pei Q, Henderson TO, et al
    Longitudinal Health-Related Quality of Life Among Patients With High-Risk Pediatric Hodgkin Lymphoma Treated on the Children's Oncology Group AHOD 1331 Study.
    J Clin Oncol. 2024 Jul 26:JCO2400038. doi: 10.1200/JCO.24.00038.
    PubMed     Abstract available
    
    
    
66. CLIFF ERS, Russler-Germain DA, Daval CJR, Kesselheim AS, et al
    US Food and Drug Administration's Directive to Deal With Delayed Confirmatory Trials: Lessons From Pralatrexate and Belinostat for T-Cell Lymphoma.
    J Clin Oncol. 2024 Jul 25:JCO2400100. doi: 10.1200/JCO.24.00100.
    PubMed     Abstract available
    
    
    
67. CAMPO E, Dierickx D, Dirnhofer S, Dunleavy K, et al
    Lymphoma Classifications, How to Develop a Future Unified Taxonomy.
    J Clin Oncol. 2024 Jul 17:JCO2400070. doi: 10.1200/JCO.24.00070.
    PubMed    
    
    
    
68. BUDDE LE, Assouline S, Sehn LH, Schuster SJ, et al
    Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.
    J Clin Oncol. 2024;42:2250-2256.
    PubMed     Abstract available
    
    
    June 2024
69. SCHODER H
    Machine Learning for Automated Interpretation of Fluorodeoxyglucose-Positron Emission Tomography Scans in Lymphoma.
    J Clin Oncol. 2024 Jun 21:JCO2400675. doi: 10.1200/JCO.24.00675.
    PubMed    
    
    
    
70. JEMAA S, Ounadjela S, Wang X, El-Galaly TC, et al
    Automated Lugano Metabolic Response Assessment in (18)F-Fluorodeoxyglucose-Avid Non-Hodgkin Lymphoma With Deep Learning on (18)F-Fluorodeoxyglucose-Positron Emission Tomography.
    J Clin Oncol. 2024 Jun 6:JCO2301978. doi: 10.1200/JCO.23.01978.
    PubMed     Abstract available
    
    
    April 2024
71. YAN C, Richard MA, Gibson CJ, He J, et al
    Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasms After Autologous Transplant for Hodgkin Lymphoma.
    J Clin Oncol. 2024 Apr 18:JCO2302547. doi: 10.1200/JCO.23.02547.
    PubMed     Abstract available
    
    
    March 2024
72. BINKLEY MS, Flerlage JE, Savage KJ, Akhtar S, et al
    International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
    J Clin Oncol. 2024 Mar 26:JCO2301655. doi: 10.1200/JCO.23.01655.
    PubMed     Abstract available
    
    
    
73. MEHTA-SHAH N, Horwitz SM
    Failing Forward in Peripheral T-Cell Lymphoma.
    J Clin Oncol. 2024 Mar 26:JCO2302658. doi: 10.1200/JCO.23.02658.
    PubMed    
    
    
    February 2024
74. CAMUS V, Thieblemont C, Gaulard P, Cheminant M, et al
    Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.
    J Clin Oncol. 2024 Feb 16:JCO2301687. doi: 10.1200/JCO.23.01687.
    PubMed     Abstract available
    
    
    
75. NEPPELENBROEK SIM, Geurts YM, Aleman BMP, Lugtenburg PJ, et al
    Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma.
    J Clin Oncol. 2024 Feb 15:JCO2301386. doi: 10.1200/JCO.23.01386.
    PubMed     Abstract available
    
    
    
76. COOPER A, Tumuluru S, Kissick K, Venkataraman G, et al
    CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Bruton's Tyrosine Kinase Inhibition.
    J Clin Oncol. 2024;42:467-480.
    PubMed     Abstract available
    
    
    January 2024
77. 
    Erratum: The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium.
    J Clin Oncol. 2024 Jan 11:JCO2302698. doi: 10.1200/JCO.23.02698.
    PubMed    
    
    
    
78. KAHL BS, Jegede OA, Peterson C, Swinnen LJ, et al
    Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma.
    J Clin Oncol. 2024 Jan 9:JCO2301912. doi: 10.1200/JCO.23.01912.
    PubMed     Abstract available
    
    
    December 2023
79. AOKI T, Jiang A, Xu A, Yin Y, et al
    Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma.
    J Clin Oncol. 2023 Dec 19:JCO2301115. doi: 10.1200/JCO.23.01115.
    PubMed     Abstract available
    
    
    
80. SARKOZY C, Thieblemont C, Oberic L, Moreau A, et al
    Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study.
    J Clin Oncol. 2023 Dec 18:JCO2301586. doi: 10.1200/JCO.23.01586.
    PubMed     Abstract available
    
    
    
81. POTT C, Jurinovic V, Trotman J, Kehden B, et al
    Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study.
    J Clin Oncol. 2023 Dec 14:JCO2300838. doi: 10.1200/JCO.23.00838.
    PubMed     Abstract available
    
    
    
82. WANG M, Siddiqi T, Gordon LI, Kamdar M, et al
    Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma (MCL): Primary Analysis of the MCL Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study.
    J Clin Oncol. 2023 Dec 10:101200JCO2302214. doi: 10.1200/JCO.23.02214.
    PubMed     Abstract available
    
    
    
83. NOERENBERG D, Briest F, Hennch C, Yoshida K, et al
    Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes.
    J Clin Oncol. 2023 Dec 6:JCO2301053. doi: 10.1200/JCO.23.01053.
    PubMed     Abstract available
    
    
    November 2023
84. HOSTER E, Delfau-Larue MH, Macintyre E, Jiang L, et al
    Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial.
    J Clin Oncol. 2023 Nov 22:JCO2300899. doi: 10.1200/JCO.23.00899.
    PubMed     Abstract available
    
    
    
85. KELLY KM, Friedberg JW
    Classic Hodgkin Lymphoma in Adolescents and Young Adults.
    J Clin Oncol. 2023 Nov 20:JCO2301799. doi: 10.1200/JCO.23.01799.
    PubMed     Abstract available
    
    
    
86. FEDERICO M, Fortpied C, Stepanishyna Y, Gotti M, et al
    Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma.
    J Clin Oncol. 2023 Nov 15:JCO2301745. doi: 10.1200/JCO.23.01745.
    PubMed     Abstract available
    
    
    October 2023
87. LUMINARI S, Fossa A, Trotman J, Molin D, et al
    Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial.
    J Clin Oncol. 2023 Oct 26:JCO2301177. doi: 10.1200/JCO.23.01177.
    PubMed     Abstract available
    
    
    
88. IACOBONI G, Navarro V, Martin-Lopez AA, Rejeski K, et al
    Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.
    J Clin Oncol. 2023 Oct 24:JCO2301097. doi: 10.1200/JCO.23.01097.
    PubMed     Abstract available
    
    
    
89. LEWIS KL, Jakobsen LH, Villa D, Smedby KE, et al
    High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.
    J Clin Oncol. 2023 Oct 5:JCO2300365. doi: 10.1200/JCO.23.00365.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum